Skip to main content
. Author manuscript; available in PMC: 2022 May 1.
Published in final edited form as: J Am Geriatr Soc. 2021 Jan 11;69(5):1328–1333. doi: 10.1111/jgs.17013

Table 2.

Results for the incidence of prescribing cascades among participants with Alzheimer’s Disease (AD).

Prescribing Cascade Cohort Antipsychotic/metoclopramide, N Antiparkinsonian use, n Person-time on Antiparkinsonian, Total, days Time on Antiparkinsonian Drug, Mean (SD), days
Incident antipsychotic/metoclopramide use with incident antiparkinsonian use 4534 36 5869 163.0 (150.1)
Polypharmacy
Prescribing cascades among those with polypharmacy in AD cohort
3485 20 3977 179.9(153.7)